Abstract
Heart failure is a leading cause of mortality in North America and most other parts of the world. Its development is secondary to diseases such as hypertension, coronary artery disease, valvular heart disease or cardiomyopathies. Current therapies for preventing heart failure include the use of diuretics, inhibitors of the renin-angiotensin-aldosterone system and β-adrenergic receptor blockers. These treatments have been moderately successful; however, the incidence of heart failure is on the rise. In view of the limited success with existing therapies it has become very important to pursue alternative strategies. One such approach could be the use of food-derived compounds that have medical benefits, and can be administered as dietary supplements. In this context, resveratrol, a polyphenol, found predominantly in grapes and berries, and a major component of red wine, has been recently drawing significant attention for its cardioprotective properties. Current research on resveratrol has focused on examining its potential in preventing or regressing defects in cardiac structure and function in experimental models of heart disease. In this paper, we will discuss the potential of resveratrol as a nutraceutical in preventing the development of heart failure in the future.
Keywords: Resveratrol, heart failure, nutraceuticals
Current Chemical Biology
Title: Potential of Resveratrol in Preventing the Development of Heart Failure
Volume: 4 Issue: 1
Author(s): Peter Wojciechowski, Xavier Lieben Louis, Sijo Joseph Thandapilly, Liping Yu and Thomas Netticadan
Affiliation:
Keywords: Resveratrol, heart failure, nutraceuticals
Abstract: Heart failure is a leading cause of mortality in North America and most other parts of the world. Its development is secondary to diseases such as hypertension, coronary artery disease, valvular heart disease or cardiomyopathies. Current therapies for preventing heart failure include the use of diuretics, inhibitors of the renin-angiotensin-aldosterone system and β-adrenergic receptor blockers. These treatments have been moderately successful; however, the incidence of heart failure is on the rise. In view of the limited success with existing therapies it has become very important to pursue alternative strategies. One such approach could be the use of food-derived compounds that have medical benefits, and can be administered as dietary supplements. In this context, resveratrol, a polyphenol, found predominantly in grapes and berries, and a major component of red wine, has been recently drawing significant attention for its cardioprotective properties. Current research on resveratrol has focused on examining its potential in preventing or regressing defects in cardiac structure and function in experimental models of heart disease. In this paper, we will discuss the potential of resveratrol as a nutraceutical in preventing the development of heart failure in the future.
Export Options
About this article
Cite this article as:
Wojciechowski Peter, Louis Lieben Xavier, Thandapilly Joseph Sijo, Yu Liping and Netticadan Thomas, Potential of Resveratrol in Preventing the Development of Heart Failure, Current Chemical Biology 2010; 4 (1) . https://dx.doi.org/10.2174/2212796811004010084
DOI https://dx.doi.org/10.2174/2212796811004010084 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issues: Pharmacological Mechanisms and Interventions in Ischemia/ Reperfusion-Induced Injury)
Current Pharmaceutical Design Retraction Note: Phytochemicals from Plants to Combat Cardiovascular Disease
Current Medicinal Chemistry Mitochondrial Injury and Targeted Intervention in Septic Cardiomyopathy
Current Pharmaceutical Design Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Current Pharmaceutical Design Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Deep Inspiration Breath-hold (DIBH) Technique to Reduce Cardiac Radiation Dose in the Management of Breast Cancer
Current Cancer Therapy Reviews Neuro-Psychological Pattern in Patients Suffering from Primitive Dilated Cardiomyopathy with Impairment in Executive Function
Current Neurovascular Research Spontaneous Coronary Artery Dissection: Does Being Unemployed Matter? Insights from the GSCAD Registry
Current Cardiology Reviews Immunomodulatory Gene Therapy in Lysosomal Storage Disorders
Current Gene Therapy Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design